GNI Group Ltd. (FRA:3G6)

Market Cap	773.60M -18.4%
Revenue (ttm)	148.45M +13.8%
Net Income	-4.74M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	8
Open	14.40
Previous Close	13.80
Day's Range	14.40 - 14.40
52-Week Range	8.80 - 26.00
Beta	n/a
RSI	51.13
Earnings Date	Feb 13, 2026

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 867
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3G6

Financial Performance

In 2024, GNI Group's revenue was 23.61 billion, a decrease of -9.22% compared to the previous year's 26.01 billion. Earnings were 1.10 billion, a decrease of -86.43%.

Financial numbers in JPY